title: Vinorelbine and interferon-alpha2c as second-line therapy in metastatic renal cell carcinoma.
abstract: Second-line treatment of patients with metastatic renal cell carcinoma (MRCC) progressing under therapy with biological response modifiers (BRM) is an unresolved issue. Thirty-seven patients with MRCC progressing under treatment with BRM received vinorelbine i.v. at a dose of 30 mg/m2 q 22 days and 4,800,000 IU interferon (IFN)-alpha2c s.c. thrice weekly. Partial remission (PR) occurred in 8% of patients, stable disease (SD) (median duration 8, range 3-35+ months) was observed in 46% of patients. Median overall survival was 15 (range 1-49) months. No major toxicities occurred. Patients with MRCC who failed first-line treatment with BRM had a high chance to enter PR or SD under combined, low-toxic therapy with vinorelbine and IFN-alpha2c.
authors.affiliation: Department of Internal Medicine I, University Hospital, Vienna, Austria.
authors.forename: M
authors.initials: M
authors.lastname: Schmidinger
authors.forename: G G
authors.initials: GG
authors.lastname: Steger
authors.forename: A C
authors.initials: AC
authors.lastname: Budinsky
authors.forename: C
authors.initials: C
authors.lastname: Wenzel
authors.forename: T
authors.initials: T
authors.lastname: Brodowicz
authors.forename: G J
authors.initials: GJ
authors.lastname: Locker
authors.forename: G
authors.initials: G
authors.lastname: Kramer
authors.forename: M
authors.initials: M
authors.lastname: Marberger
authors.forename: C C
authors.initials: CC
authors.lastname: Zielinski
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage / Q000627:therapeutic use*; D001317:Austria / Q000453:epidemiology; D002292:Carcinoma, Renal Cell / Q000401:mortality / Q000556:secondary / Q000628:therapy*; D005260:Female; D006801:Humans; D007155:Immunologic Factors / Q000008:administration & dosage / Q000627:therapeutic use*; D007167:Immunotherapy; D007262:Infusions, Intravenous; D007279:Injections, Subcutaneous; D016898:Interferon-alpha / Q000008:administration & dosage / Q000627:therapeutic use*; D007680:Kidney Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins; D016879:Salvage Therapy; D016019:Survival Analysis; D016896:Treatment Outcome; D014747:Vinblastine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000077235:Vinorelbine
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D007155:Immunologic Factors; D016898:Interferon-alpha; D011994:Recombinant Proteins; D014747:Vinblastine; D000077235:Vinorelbine; C554129:interferon alfa-2c